2014年CSCO年会9月19日（星期五）下午
全体大会(Plenary)
地点(Venue): 厦门国际会议中心2楼海峡厅
Straits Meeting Hall, 2nd Floor, Xiamen International Conference Center
荣誉主席(Honorary President)：
吴孟超 院士 Meng-Chao Wu 孙 燕 院士 Yan Sun
廖美琳 Mei-Lin Liao 管忠震 Zhong-Zhen Guan
大会主席(Conference President)：
吴一龙 Yi-long Wu 秦叔逵 Shu-Kui Qin 马 军 Jun Ma
主 持(Moderators)：
李 进 Jin Li 王绿化 Lv-Hua Wang
14:30~14:40 主席致词(President's Address) 吴孟超 院士 Meng-Chao Wu
14:40~14:50 主席致词(President's Address) 吴一龙 Yi-long Wu
颁奖典礼(Awarding Ceremony and Lecture)
14:50~14:55 终身成就奖颁奖嘉宾(Life Achievement Award Presenters)
廖美琳 Mei-Lin Liao 管忠震 Zhong-Zhen Guan
14:55~15:10 终身成就奖获奖感言(Acceptance Speech of Life Achievement Award)
15:10~15:15 年度成就奖颁奖嘉宾
(Annual Cooperation Award & Annual Achievement Award Presenters)
孙 燕 院士 Yan Sun 马 军 Jun Ma
15:15~15:30 年度成就奖获奖演讲(Acceptance Speech of Annual Achievement Award)
15:30~15:35 CSCO—默克雪兰诺肿瘤研究基金成立
默克雪兰诺中国研发中心负责人：郭 峰
主 持(Moderators)：
吴一龙 Yi-long Wu 秦叔逵 Shu-Kui Qin
大会报告(Keynote Speech)
15:35~16:05 Development of Immunotherapy for Lung Cancer
Naiyer A. Rizvi Memorial Sloan-Kettering Cancer Center, USA
16:05~16:10 Q&A
论文交流(Oral Presentations)
16:10~16:20 Safety and efficacy of the Asian subgroup of patients (pts) with EGFR-TKI- resistant advanced non-small cell lung cancer (NSCLC) in a phase I study of AZD9291 (AURA)
Myung-Ju Ahn Sungkyunkwan University, Korea
16:20~16:25 Q&A
16:25~16:40 专家点评(Abstract Discussion)
Jie Wang 王 洁 北京大学临床肿瘤学院(Beijing Cancer Hospital)
16:40~16:50 Overall survival (OS) with afatinib (A) vs gemcitabine/cisplatin (GC) in treatment- naive Chinese patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations (mut): subpopulation analysis from LUX-Lung 6 (LL6)
Yi-long Wu 吴一龙 广东省人民医院(Guangdong General Hospital)
16:50~16:55 Q&A
16:55~17:10 专家点评(Abstract Discussion)
Li Zhang 张 力 中山大学附属肿瘤医院(Sun Yat-sen University Cancer Center)
17:10~17:20 Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo- controlled trial. 阿帕替尼治疗晚期胃癌的随机、双盲、平行对照、全国多中心III期临床研究
Shu-Kui Qin 秦叔逵 南京八一医院 (No. 81 Hospital)
17:20~17:25 Q&A
17:25~17:40 专家点评(Abstract Discussion)
Jian-Ming Xu 徐建明 军事医学科学院附属医院 (No. 307 Hospital)
17:40~17:50 Efficacy and safety of regorafenib (REG) monotherapy in Chinese patients with previously treated metastatic colorectal cancer (mCRC): Subgroup analysis of the CONCUR trial
Rui-Hua Xu 徐瑞华 中山大学附属肿瘤医院 (Sun Yat-sen University Cancer Center)
17:50~17:55 Q&A
17:55~18:10 专家点评(Abstract Discussion)
Lin Shen 沈 琳 北京大学临床肿瘤学院(Beijing Cancer Hospital)
